Around 20％-30％ of patients diagnosed with prostate cancer (PCa) still havehigh-risk PCa disease (HRPC) that requires aggressive treatment.Treatment of HRPC is controversial, and multimodality therapy combining surgery, radiation therapy, and androgen deprivation therapy have been suggested.There has been a trend toward performing radical prostatectomy (RP) in HRPC and currently, robot-assisted laparoscopic RP (RARP) has become the most common approach.Number of publications related to robotic surgery inHRPC is limited in the literature.